Want to join the conversation?
Genetic testing tools company $ILMN reported a rise in 2Q16 earnings driven by notable strength across its sequencing consumable and array portfolios. Net income rose to $121.97MM or $0.82 per share from $102.25MM or $0.69 per share last year. Revenue grew to $600.12MM from $539.38MM. Non-GAAP EPS increased to $0.86 from $0.80.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.